NOVEL FORMS OF BRAIN STIMULATION & PSYCHEDELIC ASSISTED PSYCHOTHERAPY
With
Professor Paul Fitzgerald,
Director, School of Medicine and Psychology,
Australian National University, Canberra, Australia &
Principal Investigator, Paratus Clinical, Australia
RESEARCHER PROFILE
Filmed in Canberra, Australia | November 2025
Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD.
He has conducted an extensive range of experimental studies and clinical trials, focused on the development of novel treatment options for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease.
Professor Fitzgerald has a special interest in repetitive transcranial magnetic stimulation (rTMS) and other novel treatments using forms of non-invasive brain stimulation. He has had continual NHMRC grant support for 20 years and over $10 million in research support in the last 5 years. He has published several books, over 550 journal articles and been cited over 30,000 times.
He has established multiple clinical rTMS services, founded several device and clinical service companies and led a national application to MSAC in the Federal Department of Health which resulted, in 2021, in Medicare funding ($280 million in year 1) for rTMS therapy for patients with depression.
Professor Fitzgerald currently leads an innovative school at the ANU which combines both the ANU Medical Program and former Research School of Psychology focussed on education and research approaches integrating perspectives across mind, body and culture.
Source: Supplied
https://orcid.org/0000-0003-4217-8096
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
-
At the frontier of human cellular neuroscience research
Associate Professor Cedric Bardy is the Director of The Laboratory for Human Neurophysiology, Genetics & Stem Cells, located at SAHMRI. South Australia.
His current research uses preclinical, patient-derived cell models to test innovative therapeutic strategies, with a current focus on Parkinson’s disease, brain cancer and childhood dementia (Sanfilippo syndrome).
His work has established a platform to facilitate the discovery and validation of treatments for brain disorders. Their research is at the frontier of human cellular neuroscience research and translational applications that benefit global public health.
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
